Merci, madame la présidente. Thank you all for being present.
We've been hearing a number of panels, and we hear a lot about the same thing. If you'll excuse me, Mr. Orr, I won't go into the legal matters. I think you're bringing a whole new dimension to this thing as to the regulatory issues. I'd like to stick a little bit with problems and solutions on the post-market question.
I'm glad, Mr. Morgan, that you mentioned Dr. Carleton, because that's a line of questioning I was thinking of when I was listening to Dr. Laupacis. Dr. Carleton was suggesting a network of researchers who would look at specific areas in which you have effects and adverse events, and you try to discover them so that you can predict them in the future and predict how to use....
Then we had a lot of other presenters who were telling us that at the practitioner level, they would use a reporting network if that network had value to them in their practices through two-way interaction with this website. They could get the information they needed to improve their practices or to use these treatments better in the future.
Are you suggesting somewhere between those two, or a marriage of those two types of approaches, in the network you're talking about?